This page shows the latest Incivo news and features for those working in and with pharma, biotech and healthcare.
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
More recent winners, such as Xarelto, Incivo and Victrelis, show how pharmaceutical innovation is helping to transform healthcare services and improve public health.
With sales of J&J's former hepatitis C blockbuster Incivo (telaprevir) fading fast in the face of competition - falling more than 45 per cent in the first half of the
Janssen's main drugs in the area are Incivo (telaprevir), which was launched in 2011, and Olysio (simeprevir), which was approved in the US in 2013 and in the EU earlier
HCV protease inhibitors boceprevir ( Victrelis; Merck) and telaprevir ( Incivo; Vertex, Janssen) were first and, while both remained dependent on the IFN RBV backbone, the agents significantly improved virologic response rates in
Craft Award for Digital Campaign. Incivo for Janssen by Havas Lynx.
More from news
Approximately 0 fully matching, plus 16 partially matching documents found.
172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
It said that up to 10 new medicines that had proved cost effective through HTA – including Brilique, Gileyna, Sycrest, Incivo and Victrelis – were still not being reimbursed.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...